GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$23.48-4.40%
Price as of Jul 20, 2026
GLUE capital
Monte Rosa Therapeutics, Inc. capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- 0.07x
- Net debt / equity
- -0.23x
- Debt / assets
- 0.05x
- Debt / EBITDA
- -0.32x
- Net debt / EBITDA
- 0.98x
Liquidity & coverage
- Current ratio
- 9.54x
- Quick ratio
- 9.54x
- Cash ratio
- 9.38x
- Interest coverage
- —
- EBITDA / interest
- —
- Working capital
- $606.5M
Cash & dividend
- FCF / debt
- -0.50x
- Cash flow / debt
- -0.38x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.